Anhui Anke Biotechnology

Anhui Anke Biotechnology (Group) Co., Ltd. is a publicly traded biopharmaceutical company engaged in the development, manufacturing, and sale of a diverse portfolio of healthcare products. Founded in 1994 by Song Lihua, the company has established itself as a significant enterprise in China's biopharmaceutical sector. Song Lihua, who holds a doctorate and serves as the company's chairman and president, has a background as a researcher and was the director of the Anhui Provincial Institute of Biological Research. His extensive experience in biomedical research and development has been instrumental in the company's trajectory, overseeing the successful industrialization of numerous new drugs.

The company's journey began with a focus on gene and cell engineering, quickly gaining recognition through national research programs. A major milestone was its listing as one of the first companies on the Shenzhen Stock Exchange's Growth Enterprise Market (GEM) on October 30, 2009, which provided significant capital for research and development, industry layout, and market expansion. This has enabled consistent growth, with total assets expanding from approximately 542 million yuan in 2009 to over 4.95 billion yuan in 2023.

Anke Biotechnology's business model is centered on the research, production, and marketing of pharmaceuticals. Its revenue streams are generated from a wide range of products distributed both domestically across more than 30 provinces and internationally. The company's operations are diversified through several subsidiaries, covering areas from modern Chinese medicines and chemically synthesized drugs to peptide drugs and forensic DNA testing. Key products include recombinant human growth hormone (Ansomone®) and a series of recombinant human interferon alpha 2b products (Anterferon®). The portfolio extends to diagnostic kits, such as those for detecting anti-sperm antibodies, and monoclonal antibody drugs like Trastuzumab for treating breast and gastric cancers. Through strategic acquisitions, the company has also entered the field of forensic DNA testing and expanded its capabilities in precision medicine, including tumor immunotherapy and cell therapy.

Keywords: biopharmaceutical, genetic engineering, cell engineering, recombinant human growth hormone, interferon, monoclonal antibodies, precision medicine, diagnostic reagents, peptide drugs, forensic DNA testing, Chinese traditional medicines, drug development, pharmaceutical manufacturing, Song Lihua, Ansomone, Anterferon, Trastuzumab, Shenzhen Stock Exchange, GEM listed, healthcare products